[PDF] Top 20 Propuesta para la creación de un Bureau de Convenciones en la ciudad de Cuenca

... further. Tivantinib is well tolerated either as a single agent or in combination with other ...that tivantinib has no detrimental effects, even in the absence of Met ...that tivantinib retains its ... See full document

... sole treatment in potentially curable lung ...definitive treatment modality for stage II and III NSCLC ...definitive treatment of stage III disease, the greatest response is seen with ... See full document

... of lung cancer patients progressing to first- or second-generation TKIs, thus supporting the need in clinical practice for tumor genotyp- ing at the time of disease progression on or after EGFR TKI therapy ... See full document

... the treatment of ALK + -NSCLC in August ...the efficacy and safety profile of crizotinib vs chemotherapy (pemetrexed-cisplatin or pemetrexed-carboplatin) in previously untreated patients with ... See full document

... SBRT treatment until death or the last follow-up ...Response Evaluation Criteria In Solid Tumors (RECIST), according to which a complete response (CR) is defined as total tumor disappearance and a partial ... See full document

... Globally, lung cancer is associated with the highest morbidity and mortality among all cancers, and most patients already have advanced or metastatic disease when ...1 Non-small cell ... See full document

... for advanced NSCLC patients who had progressed after systemic chemotherapy or were not suitable for systemic chemotherapy. Approximately 44,000 patients participated in this program. EAP was conducted during 2001–2007 in ... See full document

... and safety between docetaxel and pemetrexed or docetaxel and vinca ...have small samples, which supply limited data to evaluate the effectiveness and safety of these ...the treatment in ... See full document

... before treatment. At the end of the treatment period, the best tumor response rate was evaluated using the same imaging technique that was used at baseline and the Response Evaluation Criteria in ... See full document

... days 1–3 every three weeks. The response rate was 44.8% (95% CI 26%–64%), being 60% for sensitive cases and 37% for refractory cases. No significant difference in the response rate was observed between sensitive cases ... See full document

... Abstract: Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains ...the treatment paradigm and provides hope for improved ...of non- ... See full document

... the treatment of advanced gastric cancer (GC) in ...therapeutic efficacy against other types of advanced solid tumors remains ...short-term efficacy and safety of apatinib or combina- ... See full document

... 0.001). Safety data were available for 609 patients, 35% of whom had at least one AE, but only 4% of patients discontinued treatment due to erlotinib-related ... See full document

... first-line treatment for Chinese NSCLC patients with EGFR ...strong efficacy for adenocarcinoma patients with both EGFR and HER2 mutations in kinase domains; this is a potential advantage of afatinib over ... See full document

... For inoperable locally advanced non-small cell lung cancer (LA-NSCLC), the efficacy of hypo- fractionated radiotherapy (Hypo-RT) has not been clearly ...in ... See full document

... of treatment to death, where living patients are censored at their last known follow-up ...of treatment to either recurrence (local, regional or distant) or death, where a patient is censored at the time of ... See full document

... prospectively or retrospectively [17–20]. Complete dis- appearance of abnormal FDG accumulation is an indica- tor of a low probability of local recurrence and better prognosis after treatment such as surgery, ... See full document

... The isosorbide mononitrate sustained release tablet was as donor of NO in this study, and the plasma concentration was more stable. It could improve the sensitivity of old patients with IIIb~IV NSCLC during chemotherapy, ... See full document

... programmed cell death 1 (PD-1) receptor on T cells, thus releasing an otherwise physio- logical immune brake employed by malignant cells to allow for tumour ...with inoperable or metastatic mela- noma, ... See full document

... of treatment-free interval before relapse depends on how frequent and exhaustive are disease assessments after the end of ...initial treatment was rechallenged if the treatment- free interval was ⱖ 8 ... See full document